Company profile for The Medicines Company

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Paci...
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland. The Company was founded in 1996 and is publicly traded on the Nasdaq exchange under the ticker symbol MDCO.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
8 Sylvan Way Parsippany, NJ 07054
Telephone
Telephone
+1 973-290-6000
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Novartis touts more late-stage data for inclisiran
Novartis touts more late-stage data for inclisiran

12 Nov 2021

// Nicole DeFeudis ENDPTS

https://endpts.com/novartis-touts-more-late-stage-data-for-inclisiran-the-once-centerpiece-heart-drug-spurned-by-the-fda/

Nicole DeFeudis ENDPTS
12 Nov 2021

https://endpts.com/novartis-9-7b-pcsk9-drug-nabs-first-ok-now-comes-the-challenge-of-finding-a-market/

Amber Tong ENDPTS
12 Dec 2020

http://www.pmlive.com/pharma_news/novartis_picks_up_inclisiran_after_completion_of_medco_acquisition_1321708

Lucy Parsons PM LIVE
08 Jan 2020

https://www.globenewswire.com/news-release/2020/01/06/1966217/0/en/Novartis-completes-tender-offer-for-all-outstanding-shares-of-The-Medicines-Company.html

GLOBE NEWSWIRE
08 Jan 2020

https://www.globenewswire.com/news-release/2020/01/06/1966217/0/en/Novartis-completes-tender-offer-for-all-outstanding-shares-of-The-Medicines-Company.html

GLOBE NEWSWIRE
07 Jan 2020

https://www.globenewswire.com/news-release/2020/01/06/1966217/0/en/Novartis-completes-tender-offer-for-all-outstanding-shares-of-The-Medicines-Company.html

GLOBE NEWSWIRE
07 Jan 2020

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty